• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Dr Kelly Moffitt joins ProAxsis team
Share
Announcements, News

Dr Kelly Moffitt joins ProAxsis team

May 9, 2016
-
Posted by Webmaster

ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior Project Manager, and will report in to the CEO, Dr David Ribeiro. Dr Moffitt worked in a number of research roles at Queen’s University, Belfast, prior to successfully obtaining a PRINCE2 Practitioner qualification in project management. This included a three-year period, working on a collaborative US-Ireland Cystic Fibrosis project with Professor Stuart Elborn. In her new role, she will be responsible for leading a number of R&D and commercial projects, which will be critical to the ongoing success of the company.

Dr David Ribeiro, CEO of ProAxsis, said: “Kelly was part of the team at Queens that originally came up with the idea of developing an assay for measuring the active form of neutrophil elastase in sputum from patients with chronic respiratory diseases such as cystic fibrosis and COPD. To attract someone of Kelly’s specific experience and knowhow to join us is a significant boost for the company.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

May 9, 2016

Related News

Other posts that you should not miss.
Conferences, Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis CEO to present at Biotech in Europe

September 23, 2016
-
Posted by Webmaster

Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in Basel …

Read More
September 23, 2016
Posted by Webmaster
News, ProteaseTag®

ProAxsis provides update on commercialisation progress

November 21, 2017
-
Posted by Webmaster

Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in …

Read More
November 21, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis abstracts at 2017 American Thoracic Society Conference

May 5, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …

Read More
May 5, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis to present at 2016 American Thoracic Society Conference
NEXT POST →
"ProActive Investors UK" interviews David Ribeiro
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
  • December 2, 2020
    ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
46 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
46 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
67 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
87 days ago
- ProAxsis
Copyright © 2016-2018 - ProAxsis - All rights reserved. 
Dr Kelly Moffitt joins ProAxsis team | ProAxsis